Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 6/20 | 0.58 |
| ▸ | DRD1 | P21728 | 3/20 | 0.58 |
| ▸ | DRD2 | P14416 | 3/20 | 0.56 |
| ▸ | HTR1A | P08908 | 4/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 2/20 | 0.48 |
| ▸ | HTR2C | P28335 | 2/20 | 0.48 |
| ▸ | DRD4 | P21917 | 2/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6969843 | 0.99 | DRD3 (0.57) | DRD3DRD1DRD2HTR1ASIGMAR1 | |
| SCHEMBL6965751 | 0.79 | HSD11B1 (0.55) | SIGMAR1GAA | |
| SCHEMBL6960377 | 0.79 | HRH1 (0.50) | DRD3DRD1HTR1ASIGMAR1ALDH1A1 | |
| SCHEMBL6963499 | 0.78 | HRH1 (0.49) | DRD3DRD1ADRA1DADRA1AADRA1B | |
| Hydrochloric Acid SCHEMBL6960160 | 0.78 | HRH1 (0.49) | DRD3DRD1HTR1AALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL6970215 | 0.77 | HRH1 (0.49) | DRD3DRD1ADRA1DADRA1AADRA1B | |
| SCHEMBL13711971 | 0.77 | KCNH2 (0.71) | DRD3DRD1DRD2HTR1APOLB | |
| SCHEMBL6960633 | 0.77 | HRH1 (0.47) | DRD3DRD1DRD2HTR1ASIGMAR1 | |
| SCHEMBL6973725 | 0.76 | HRH1 (0.47) | DRD3DRD1DRD2HTR1ASIGMAR1 | |
| SCHEMBL9032398 | 0.75 | GRIN1 (0.80) | DRD3DRD1DRD2HTR1AGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0934312-B1 | 1,4-DISUBSTITUTED PIPERAZINES | NOVO NORDISK AS (DK) | 2003-03-19 | — | — | EP | claimed |
| US-20020045610-A1 | Use of N-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis | LUBRIZOL CORPORATION, THE | 2002-04-18 | — | — | US | claimed |
| EP-1135129-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2001-09-26 | — | — | EP | claimed |
| WO-2000032193-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2000-06-08 | — | — | WO | claimed |
| EP-0934312-A1 | 1,4-DISUBSTITUTED PIPERAZINES | NOVO NORDISK A/S (DK) | 1999-08-11 | — | — | EP | claimed |
| WO-1998015548-A1 | 1,4-DISUBSTITUTED PIPERAZINES | NOVO NORDISK A/S (DK) | 1998-04-16 | — | — | WO | claimed |
| EP-0934312-B1 | 1,4-DISUBSTITUTED PIPERAZINES | NOVO NORDISK AS (DK) | 2003-03-19 | — | — | EP | disclosed |
| US-20020045610-A1 | Use of N-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis | LUBRIZOL CORPORATION, THE | 2002-04-18 | — | — | US | disclosed |
| EP-1135129-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2001-09-26 | — | — | EP | disclosed |
| US-6133268-A | 1,4-disubstituted piperazines | NOVO NORDISK A/S (DK) | 2000-10-17 | — | — | US | disclosed |
| WO-2000032193-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2000-06-08 | — | — | WO | disclosed |
| US-6040302-A | ANTIINFLAMMATORY AGENTS TREATING RHEUMATOID ARTHRITIS, MIGRAINE OR ITCHING, INSULIN RESISTANCE IN NON-INSULIN-DEPENDENT DIABETES MELLITUS AND AGEING-ASSOCIATED OBESITY | NOVO NORDISK A/S (DK) | 2000-03-21 | — | — | US | disclosed |
| US-6040289-A | ACTIVE DRUG TREATING OBESITY | DR. KARL THOMAE GMBH (DE) | 2000-03-21 | — | — | US | disclosed |
| US-6004961-A | ANTIINFLAMMATORY AGENTS, ANALGESICS; NON-INSULIN-DEPENDENT DIABETES; AGE-RELATED OBESITY; DIBENZO(D,G)(1,3,6)DIOXAZOCINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1999-12-21 | — | — | US | disclosed |
| EP-0934312-A1 | 1,4-DISUBSTITUTED PIPERAZINES | NOVO NORDISK A/S (DK) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998015548-A1 | 1,4-DISUBSTITUTED PIPERAZINES | NOVO NORDISK A/S (DK) | 1998-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045610-A1 | Use of N-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis | VEGFA, KDR, FLT4 | DRD3 3633/4885DRD1 3707/4885DRD2 2668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.